Lantern Pharma IncNASDAQ LTRN Stock Report

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm's therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. Its products include LP-100, LP-300, LP-184, and LP-284, and an Antibody Drug Conjugate (ADC) program. LP-100 is in Phase II clinical trial in metastatic, castration-resistant and prostate cancer. LP-300 is focused on targeting phase II trial, in never smoking patients with NSCLC in combination with chemotherapy. LP-184 is a synthetic small molecule drug with nanomolar potency. LP-284, the stereoisomer (enantiomer) of LP-184, has shown in-vitro anticancer activity in hematological cancers. ADC Program based on the recognition of antibody drug conjugates as a therapeutic approach for cancer treatment.